Augurex Life Sciences Corp.

Augurex Life Sciences Corp. · company speakers →

Augurex Life Sciences Corp. is a commercial-stage diagnostics company dedicated to translating disease-specific biology into clinically relevant laboratory tests for autoimmune and inflammatory conditions. Our core expertise centers on targeting 14-3-3eta, a joint-derived protein integral to inflammatory disease pathways, to address unmet needs in earlier diagnosis, prognosis, and disease monitoring. Augurex pioneered 14-3-3eta–based diagnostics in inflammatory arthritis. The 14-3-3eta blood test is approved as JOINTstat® in Canada and Great Britain and is used to support clinical decision-making in rheumatoid arthritis. In the U.S., 14-3-3eta testing is available via LDT pathways using analyte-specific reagents. Our diagnostic portfolio also includes SPINEstat® (Anti-14-3-3eta Multiplex Autoantibody Immunoassay), a first-in-class laboratory diagnostic for axial spondyloarthritis (axSpA), approved in Canada and the UK, and recently recognized by the U.S. FDA with Breakthrough Device designation. SPINEstat® measures multiple autoantibodies to 14-3-3eta. When combined with clinical findings, signs and symptoms consistent with axSpA, it aids in diagnosis, addressing the serious and prolonged multi-year diagnostic delay that arises when inflammatory back pain is misclassified as mechanical. FDA Breakthrough designation underscores SPINEstat’s potential to improve early, accurate differentiation of inflammatory versus mechanical back pain. Designed for laboratory medicine, Augurex technologies integrate seamlessly into existing clinical laboratory workflows and are in use or advanced validation across major labs in North America, with international expansion underway. We collaborate with clinicians, academic centers, industry partners, and patient advocacy organizations to ensure real-world utility and clinical impact by advancing biology-driven diagnostics that help get the right patients to specialty care sooner.

Is this you? Claim this profile →